利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.019 秒)

    IMP-3 OLIGOPEPTIDES AND VACCINES INCLUDING THE SAME
    12.
    发明申请
    IMP-3 OLIGOPEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
    IMP-3寡核苷酸和疫苗，包括它们

    公开(公告)号：US20120308590A1

    公开(公告)日：2012-12-06

    申请号：US13513120

    申请日：2010-11-30

    申请人： Yasuharu Nishimura ,  Michiko Harao ,  Yusuke Tomita ,  Yusuke Nakamura ,  Takuya Tsunoda

    发明人： Yasuharu Nishimura ,  Michiko Harao ,  Yusuke Tomita ,  Yusuke Nakamura ,  Takuya Tsunoda

    IPC分类号： A61K39/00 ,  C07H21/04 ,  A61K31/7088 ,  A61P35/00 ,  A61K35/14 ,  C07K7/06 ,  C12N5/078

    CPC分类号： A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/57 ,  C07K14/47

    摘要： Oligopeptides having cytotoxic T cell inducibility and suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. Notable examples include oligopeptides having the amino acid sequence of SEQ ID NO: 1, 3, 5 or 6, wherein 1, 2, or several amino acids are optionally substituted, deleted, inserted or added so long as they retain the cytotoxic T cell inducibility of the original oligopeptides. Pharmaceutical formulations or “drugs” related to such oligopeptides suitable for treating or preventing cancers or tumors, as well as the post-operative recurrence thereof, are also described.

    摘要翻译： 本文描述了具有细胞毒性T细胞诱导能力并且适用于癌症免疫治疗，尤其是癌症疫苗的背景下的寡肽。 值得注意的实例包括具有SEQ ID NO：1,3,5或6的氨基酸序列的寡肽，其中1,2或几个氨基酸任选被取代，缺失，插入或加入，只要它们保留细胞毒性T细胞诱导性即可 的原始寡肽。 还描述了与适用于治疗或预防癌症或肿瘤的这种寡肽相关的药物制剂或药物，以及其术后复发。

    SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
    14.
    发明授权
    SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same 有权
    SPARC衍生的肿瘤排斥抗原肽和包含其的药物

    公开(公告)号：US08053557B2

    公开(公告)日：2011-11-08

    申请号：US12304350

    申请日：2007-06-15

    申请人： Yasuharu Nishimura ,  Yoshiaki Ikuta ,  Shuichi Nakatsuru

    发明人： Yasuharu Nishimura ,  Yoshiaki Ikuta ,  Shuichi Nakatsuru

    IPC分类号： A61K38/08

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  C07K14/47 ,  C07K16/18

    摘要： It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.

    摘要翻译： 本发明的目的是鉴定能够诱导人类杀伤T细胞和对肿瘤具有细胞毒性活性的辅助性T细胞的SPARC蛋白衍生肽，并提供用于对各种类型的患者进行肿瘤免疫治疗的手段 的过表达SPARC的癌症。 本发明提供以下任一项的肽：（A）由SEQ ID NO：1〜3中任一项所示的氨基酸序列构成的肽; 或（B）由包含相对于由SEQ ID NO：1至3中任一项所示的氨基酸序列组成的肽取代或添加一个或数个氨基酸的氨基酸序列组成的肽，以及 其具有诱导细胞毒性（杀伤）T细胞的能力。

    SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND MEDICAMENTS COMPRISING THE SAME
    17.
    发明申请
    SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND MEDICAMENTS COMPRISING THE SAME 有权
    SPARC衍生的肿瘤抑制抗原肽和包含其的药物

    公开(公告)号：US20100152421A1

    公开(公告)日：2010-06-17

    申请号：US12304350

    申请日：2007-06-15

    申请人： Yasuharu Nishimura ,  Yoshiaki Ikuta ,  Shuichi Nakatsuru

    发明人： Yasuharu Nishimura ,  Yoshiaki Ikuta ,  Shuichi Nakatsuru

    IPC分类号： C07K7/06 ,  C07K16/30 ,  C12N5/0783

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  C07K14/47 ,  C07K16/18

    摘要： It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.

    摘要翻译： 本发明的目的是鉴定能够诱导人类杀伤T细胞和对肿瘤具有细胞毒性活性的辅助性T细胞的SPARC蛋白衍生肽，并提供用于对各种类型的患者进行肿瘤免疫治疗的手段 的过表达SPARC的癌症。 本发明提供以下任一项的肽：（A）由SEQ ID NO：1〜3中任一项所示的氨基酸序列构成的肽; 或（B）由包含相对于由SEQ ID NO：1至3中任一项所示的氨基酸序列组成的肽取代或添加一个或数个氨基酸的氨基酸序列组成的肽，以及 其具有诱导细胞毒性（杀伤）T细胞的能力。

    CDC45L peptides and vaccines including the same
    19.
    发明授权
    CDC45L peptides and vaccines including the same 有权
    CDC45L肽和疫苗包括相同的

    公开(公告)号：US08586547B2

    公开(公告)日：2013-11-19

    申请号：US13321812

    申请日：2010-05-25

    申请人： Yasuharu Nishimura ,  Yusuke Tomita ,  Yusuke Nakamura ,  Takuya Tsunoda

    发明人： Yasuharu Nishimura ,  Yusuke Tomita ,  Yusuke Nakamura ,  Takuya Tsunoda

    IPC分类号： A61K38/08 ,  A61K38/04

    CPC分类号： C07K14/4748 ,  A61K39/0011 ,  A61K2039/5158

    摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 18, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of the present invention can be used for treating cancer.

    摘要翻译： 本发明提供分离的肽或衍生自SEQ ID NO：18的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。 肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。 本发明还提供包含这些肽的药物组合物。 本发明的肽可用于治疗癌症。